Built to provide research that’s more actionable and strategically valuable, The Business Research Company’s 2026 market reports include market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, broader supply chain intelligence, emerging startup tracking, and in-depth product insights.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Growth From $12.36 Billion In 2026 To $13.59 Billion By 2030 At A CAGR Of 2.4%
The anti-vascular endothelial growth factor therapeutics market size has seen slight growth in recent years. It is projected to increase from $12.17 billion in 2025 to $12.36 billion in 2026, at a compound annual growth rate (CAGR) of 1.6%. The market’s expansion in the past can be attributed to the approval of lucentis and eylea, the rising prevalence of age-related macular degeneration, the growing incidence of diabetic retinopathy, advancements in molecular biology for angiogenesis inhibition, and the expansion of hospital ophthalmology services.
The anti-vascular endothelial growth factor therapeutics market is projected to experience consistent expansion over the upcoming years. Its valuation is anticipated to reach $13.59 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 2.4%. This anticipated growth during the forecast period can be credited to factors such as the introduction of advanced anti-VEGF therapeutics, a rise in investment within precision oncology, increased penetration of the biosimilar market, escalating healthcare spending in developing economies, and the uptake of combination therapies for retinal conditions. Key developments expected during this period involve the greater use of anti-VEGF treatments in ophthalmology, the expansion of targeted cancer therapies, the creation of biosimilar anti-VEGF medications, an aging global population stimulating treatments for AMD, and the proliferation of outpatient and specialized clinics.
Get A Free Sample Report With In-Depth Market Insights:
Anti-Vascular Endothelial Growth Factor Therapeutics Market Demand Drivers: What’s Powering Industry Growth?
The anticipated growth of the anti-vascular endothelial growth factor therapeutics market is driven by the rising prevalence of ophthalmic diseases. Ophthalmic disease prevalence denotes the count or percentage of individuals within a specific population diagnosed with or displaying particular eye conditions or illnesses. Anti-vascular endothelial growth factor (VEGF) treatments are instrumental in lowering the incidence of ophthalmic diseases by effectively managing conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. As an illustration, in August 2023, the World Health Organization, an international public health organization situated in Switzerland, reported that globally, approximately 2.2 billion people experience near or distance vision impairment, and 1 billion people suffer from near or distance vision impairment. Furthermore, among these, 88.4 million are affected by refractive error, 94 million by cataracts, 8 million by age-related macular degeneration, and around 3.9 million by diabetic retinopathy. Consequently, the increasing prevalence of ophthalmic diseases is a key factor propelling the expansion of the anti-vascular endothelial growth factor therapeutics market.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Segment Landscape And Growth Outlook
The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –
1) By Product: Eylea, Lucentis, Beovu
2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration
3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users
Anti-Vascular Endothelial Growth Factor Therapeutics Market Innovation Trends: What Developments Are Reshaping The Industry?
Companies operating in the anti-VEGF therapeutics market are increasingly forging strategic partnerships to accelerate the development, commercialization, and adoption of VEGF inhibitors. Such collaborations enable companies to leverage complementary expertise, access innovative technologies, and expand their market presence. As an illustration, in January 2025, Teva Pharmaceuticals International GmbH, a Switzerland-based subsidiary of Teva Pharmaceutical Industries specializing in biosimilars and complex generics, entered a strategic collaboration with Klinge Biopharma GmbH and Formycon AG. This partnership aims to commercialize FYB203, a biosimilar candidate to Eylea (aflibercept), in Europe (excluding Italy) and Israel. Under this arrangement, Teva utilizes its established commercial infrastructure and distribution network to strengthen its presence in the anti-VEGF therapeutics market. Formycon AG is responsible for developing FYB203, and Klinge Biopharma GmbH holds exclusive global commercialization rights for the product.
Anti-Vascular Endothelial Growth Factor Therapeutics Market Competitive Landscape: Who Leads The Industry?
Major companies operating in the anti-vascular endothelial growth factor therapeutics market are F. Hoffmann-La Roche AG, Pfizer Inc., Coherus BioSciences Inc., Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc., Allergan Inc., Novartis AG, Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited
View The Full Anti-Vascular Endothelial Growth Factor Therapeutics Market Report:
Anti-Vascular Endothelial Growth Factor Therapeutics Market Regional Distribution: Which Areas Power Market Growth?
North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2025. Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model